VolitionRX Ltd (VNRX) — Titan Protect Analysis

VNRX

VolitionRX Ltd

Healthcare · ·

$1.79

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$18M

Total market value of the company

Trailing P/E

N/A

Forward P/E

0.20

Based on estimated future earnings — lower means cheaper

Rev Growth

+133.2%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$20.00

+1017% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 4 analysts covering this stock

About VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response a

https://volition.com

Country: United States Employees: 75 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.577

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.2065

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.694

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-61.9%

Historical annualised return based on price data

Max Drawdown

-89.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.03

Moves slightly more than the broader market

52W High

$18.80

90% below the year high

52W Low

$1.91

-6% above the year low

Avg Volume

630,640

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.25

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,077.9%

Profit from core operations before interest and tax

Free Cash Flow

$-8,515,099

Negative — the business is spending more than it generates

Revenue (TTM)

$2M

Total revenue over the last 12 months

Net Income

$-23,357,028

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$24.00

Target Median

$20.00

Target Low

$16.83

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go